LEO Pharma has closed its acquisition of dersimelagon from Tanabe Pharma after the FDA accepted the drug's NDA for filing and granted Priority Review, with a PDUFA date expected by the end of February 2027.
|Slideshows|June 26, 2018
- Dermatology Times, July 2018 (Vol. 39, No. 07)
- Volume 39
- Issue 7
Four questions every provider should ask about digital technology
Author(s)Dermatology Times Staff
There are four questions physicians should ask when considering using digital healthcare technologies, says Michael L. Hodgkins, M.D., chief medical officer for the American Medical Association. View the slideshow for more information.
Advertisement
There are four questions physicians should ask when considering using digital healthcare technologies, says Michael L. Hodgkins, M.D., chief medical officer for the American Medical Association. View the slideshow for more information.See:Â "More patients want digital health"Â
Articles in this issue
about 8 years ago
Pricing patients out of healthcare?about 8 years ago
Image IQ: When is a biopsy required?about 8 years ago
Rare tumors and fibrotic skin lesionsabout 8 years ago
New Drugs Roundup: Dermatologyabout 8 years ago
The top 7 mobile apps in dermatologyabout 8 years ago
Medicine no longer apoliticalabout 8 years ago
Study: Novel 670 nm wavelength works for benign pigmented lesionsabout 8 years ago
I use social media and now I might lose my license?about 8 years ago
Complications low with chemical peels in darker skinAdvertisement
Related to this article
Sol-Gel Technologies has completed patient follow-up in its pivotal phase 3 trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, with top-line results expected in late November 2026.
Two small clinical studies evaluated skincare and dermabrasion for changes in skin quality among individuals taking medical weight loss medications.
Two-year POETYK PsA-2 data showed sustained ACR and minimal disease activity responses with deucravacitinib and no new safety signals.
Faculty from the Cutaneous Oncology Workshop answer practical questions spanning skin cancer prevention, diagnosis, treatment, and follow-up.
Two new Neutrogena facial sunscreens incorporate bemotrizinol, the first new sunscreen active ingredient added to the US OTC monograph in decades.
Longer treatment duration was independently associated with VASI improvement, while publicly insured patients experienced higher topical JAK inhibitor denial rates.
Though convenient, SPF-infused cosmetics rarely deliver their labeled protection level in real-world use, underscoring the continued need for a dedicated broad-spectrum sunscreen as the foundation of any routine.
Advertisement
Advertisement
Trending on Dermatology Times
1
Neutrogena Launches New Sunscreens With Newly Permitted UV Filter Bemotrizinol
2
Two-Year POETYK PsA-2 Data Show Durable Deucravacitinib Responses in Psoriatic Arthritis
3
Longer Topical JAK Inhibitor Treatment Linked to Vitiligo Improvement in Real-World Study
4
Sun Protection in Beauty Routines: Is SPF Makeup Enough?
5